List of Excipients in Branded Drug PYLERA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	PYLERA	bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride (140 mg/125 mg/125 mg)	54868-6151	GELATIN
Physicians Total Care Inc	PYLERA	bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride (140 mg/125 mg/125 mg)	54868-6151	LACTOSE MONOHYDRATE
Physicians Total Care Inc	PYLERA	bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride (140 mg/125 mg/125 mg)	54868-6151	MAGNESIUM STEARATE
Physicians Total Care Inc	PYLERA	bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride (140 mg/125 mg/125 mg)	54868-6151	TALC
Physicians Total Care Inc	PYLERA	bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride (140 mg/125 mg/125 mg)	54868-6151	TITANIUM DIOXIDE

PYLERA Excipient Strategy and Commercial Opportunities

Last updated: August 17, 2026

PYLERA is a fixed-dose hard-gelatin capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride. Its commercial value lies in simplifying a complex Helicobacter pylori eradication regimen, while its main product weaknesses are pill burden, gastrointestinal tolerability, antibiotic stewardship concerns, and the need to coadminister omeprazole. Excipient innovation can target stability, capsule robustness, swallowability, adherence, packaging, and differentiated lifecycle products rather than changing the active pharmaceutical ingredients.

What is PYLERA and how is it administered?

PYLERA is approved with omeprazole for the eradication of H. pylori infection in adults. Each capsule contains:

Component	Amount per capsule	Function
Bismuth subcitrate potassium	140 mg	Bismuth antimicrobial and mucosal-protective component
Metronidazole	125 mg	Nitroimidazole antibacterial
Tetracycline hydrochloride	125 mg	Tetracycline-class antibacterial

The labeled regimen is three capsules four times daily for 10 days, together with omeprazole 20 mg twice daily. The full course therefore requires 120 PYLERA capsules and 20 omeprazole doses.[1]

The dosing schedule creates a central commercial opportunity: a formulation or packaging improvement that reduces administration errors without altering the approved active ingredients.

What excipients are used in PYLERA?

The FDA prescribing information identifies colloidal silicon dioxide and magnesium stearate as inactive ingredients in the capsule formulation. The capsule shell contains gelatin and titanium dioxide. The printing ink contains black iron oxide and shellac.[1]

The excipient system is functionally conservative:

• Colloidal silicon dioxide supports powder flow during high-dose capsule filling.
• Magnesium stearate supports lubrication and ejection during manufacturing.
• Gelatin provides the hard-capsule shell.
• Titanium dioxide and black iron oxide support capsule appearance and product identification.
• Shellac is used in the capsule imprinting system.

The label does not describe a modified-release system, enteric coating, amorphous solid dispersion, taste-masking layer, or polymeric delivery platform.

Which excipient attributes matter most for PYLERA?

The highest-value excipient decisions concern manufacturability and product usability. The product combines three chemically different actives with a substantial fill mass and a four-times-daily dosing schedule.

Powder flow and content uniformity

Bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride have different particle properties, densities, and electrostatic behavior. A formulation must maintain uniform distribution during blending and capsule filling.

Colloidal silicon dioxide can improve flow and reduce cohesion, but excess glidant may affect dissolution, powder segregation, and capsule-fill consistency. Magnesium stearate concentration and blending time also require control because over-lubrication can reduce wetting and slow dissolution.

A generic or reformulated product would need to establish:

• Blend uniformity across the full capsule-filling run.
• Uniformity of dosage units for all three actives.
• Dissolution profiles for each active.
• Compatibility under accelerated and long-term storage.
• Control of segregation during transfer and filling.

The three-active composition makes process validation more demanding than for a single-ingredient capsule.

Moisture and chemical stability

Tetracycline-class compounds are sensitive to degradation pathways that can be accelerated by moisture, heat, and unfavorable pH conditions. Metronidazole and bismuth salts also impose separate stability considerations.

Excipient and packaging strategy should therefore focus on:

• Low-moisture excipients.
• Controlled capsule-shell water content.
• High-barrier blister packaging.
• Desiccant integration where justified.
• Protection from heat and humidity during distribution.
• Stability-indicating analytical methods for all three actives and relevant degradants.

A high-barrier aluminum-aluminum blister may offer a stronger differentiation route than a bottle, especially in humid markets. Unit-dose blistering also aligns with the 10-day regimen and may reduce missed or duplicated doses.

What formulation patents could protect a PYLERA follow-on product?

Potentially protectable formulation features include the composition, particle engineering, capsule architecture, packaging system, and administration schedule. The commercial value of each claim type differs.

Claim category	Potential subject matter	Commercial value
Composition	Specific ratios of bismuth, metronidazole, and tetracycline	Broadest product coverage, but vulnerable to prior-art challenges
Excipient system	Defined glidant, lubricant, binder, or disintegrant ranges	Moderate value if linked to measurable performance
Particle engineering	Co-milling, granulation, controlled particle size, or surface treatment	Stronger manufacturing differentiation
Capsule design	Multiple compartments, sequential release, or color-coded dose units	Potential adherence and stability advantages
Packaging	Regimen-specific blister or moisture-control system	Useful commercial protection, usually narrower
Method of use	Dosing combinations, administration timing, or treatment duration	Depends on novelty and FDA-label support
Manufacturing process	Low-shear blending, moisture-controlled filling, or segregation control	Can create practical barriers even when composition claims are narrow

The strongest patent strategy would generally combine composition claims with process and packaging claims. A formulation patent limited to a routine lubricant or standard capsule shell would face a higher obviousness risk unless it produced a documented dissolution, stability, or content-uniformity benefit.

What patent barriers affect PYLERA generic entry?

PYLERA is a small-molecule combination product, so biosimilar exclusivity does not apply. Generic competition would proceed through the abbreviated new drug application pathway if the applicant can demonstrate pharmaceutical equivalence, bioequivalence, and compliance with applicable FDA requirements.

The relevant intellectual-property review includes:

• Current FDA Orange Book patent listings for the PYLERA NDA.
• Listed expiration dates and pediatric extensions.
• Any litigation initiated after a Paragraph IV certification.
• Regulatory exclusivity associated with the approved product.
• Patents covering the combination, manufacturing process, or regimen.
• Patent ownership and licensing arrangements involving the current NDA holder.

A Paragraph IV challenge could target listed patents before expiry. A generic applicant could also pursue a section viii statement for a method-of-use patent where the proposed label omits the patented use, although that strategy is less relevant where the core H. pylori eradication indication is central to the product.

When does PYLERA lose exclusivity?

PYLERA’s market protection depends on the interaction of FDA regulatory exclusivity, listed patents, and litigation outcomes. Regulatory exclusivity and patent expiry are separate concepts.

The original PYLERA product was approved by the FDA in 2006 under NDA 050786.[1] The product is now an established small-molecule combination therapy. Its commercial protection is therefore more likely to depend on patent status, manufacturing complexity, prescriber familiarity, and formulary positioning than on remaining regulatory exclusivity.

The Orange Book, FDA patent records, and federal court dockets determine whether a specific generic launch is blocked. A product-level expiry date should not be inferred solely from the approval year.

What is the Orange Book status of PYLERA?

PYLERA is listed in FDA drug databases as a prescription oral capsule product under NDA 050786.[2] The Orange Book is the controlling public source for listed patents, exclusivity, therapeutic-equivalence evaluations, and approved product information.

For commercial diligence, the relevant questions are:

1. Are patents currently listed against the NDA?
2. What are the expiration dates, including any patent-term adjustment?
3. Has pediatric exclusivity extended a listed patent?
4. Have any Paragraph IV notices triggered Hatch-Waxman litigation?
5. Is an approved generic listed as therapeutically equivalent?
6. Does the current label contain protected use information?

The answers can change through patent litigation, delisting, settlements, regulatory amendments, or approval of a competing product.

How strong is the PYLERA patent estate?

The core active-ingredient combination is technically identifiable and likely exposed to prior-art analysis because bismuth, metronidazole, and tetracycline have long histories in H. pylori treatment. The most defensible lifecycle claims would therefore be claims tied to a specific formulation performance or manufacturing advantage.

Relative strength of possible claim types

Claim type	Relative strength	Reason
Broad three-active composition	Low to moderate	Prior art and obviousness exposure
Narrow active ratio	Moderate	Stronger if linked to clinical or dissolution performance
Excipient range	Low to moderate	Requires unexpected technical effect
Moisture-stable formulation	Moderate to strong	Stronger if stability data show a material improvement
Segregation-resistant manufacturing process	Moderate	Can create manufacturing barriers
Regimen-specific packaging	Moderate	Useful for adherence, but claim scope may be narrow
New delivery system	Stronger	Potentially meaningful if it improves tolerability or administration

A practical exclusivity strategy should rely on a portfolio rather than one broad formulation patent. Manufacturing know-how may be as important as patent claims because three-active blend uniformity and stability control can increase the cost and time required for generic replication.

What excipient-based commercial opportunities exist for PYLERA?

1. Adherence-oriented blister packaging

The current four-times-daily schedule creates a significant risk of missed doses. A calendarized blister could separate morning, midday, evening, and bedtime administration while pairing the product with omeprazole instructions.

A commercial package could include:

• Ten daily dose cards.
• Four clearly labeled daily dosing windows.
• Separate omeprazole compartments or an integrated co-pack.
• Visual warnings about alcohol use during and after metronidazole therapy.
• Administration instructions addressing tetracycline interactions with minerals and dairy products.

The primary value would be adherence and medication-error reduction rather than a new excipient.

2. Moisture-protective packaging

A high-barrier blister may improve stability in hot and humid regions. This opportunity is particularly relevant for international markets where storage conditions are less controlled.

Potential product claims could relate to:

• Extended shelf life.
• Reduced degradation under accelerated humidity.
• Lower package moisture transmission.
• Better preservation of capsule appearance and performance.

Packaging improvements may support premium pricing where the product is distributed through pharmacies with limited climate control.

3. Lactose-free and allergy-positioned variants

The cited PYLERA label identifies colloidal silicon dioxide, magnesium stearate, gelatin, titanium dioxide, black iron oxide, and shellac as inactive materials.[1] A reformulation could evaluate alternatives to animal-derived gelatin or other shell components for markets requiring vegetarian, religious, or dietary certification.

Potential commercial variants include:

• Hypromellose capsules.
• Gelatin-free capsules.
• Titanium-dioxide-free shells.
• Shellac-free printing systems.
• Region-specific excipient declarations.

Any substitution would require compatibility, dissolution, stability, capsule integrity, and regulatory bridging work. The opportunity is strongest in markets where capsule composition affects prescribing, procurement, or patient acceptance.

4. Improved swallowability

Patients take three capsules per administration and 12 capsules per day. Capsule size, shell friction, surface finish, and packaging ergonomics therefore have commercial importance.

Potential approaches include:

• Smaller capsules through higher-density granulation.
• Capsule-in-capsule or multiparticulate designs.
• Low-friction capsule surfaces.
• Optimized fill density.
• Dose-card packaging that reduces the perceived complexity of the regimen.

A smaller capsule may require changes in particle size, granulation, or active loading. These changes could affect dissolution and bioequivalence.

5. Combination co-pack with omeprazole

PYLERA requires omeprazole coadministration. A coordinated pack could reduce dispensing complexity and increase product retention at the pharmacy level.

Commercial models include:

• PYLERA plus generic omeprazole in a single treatment pack.
• A blister with scheduled PYLERA and omeprazole doses.
• Market-specific packs using locally approved omeprazole strengths.
• Specialty-pharmacy adherence programs.

The primary regulatory question is whether the co-pack remains a packaging presentation of separately approved products or requires additional combination-product review.

What manufacturing and IP barriers affect competitors?

A competing manufacturer must reproduce a multi-active oral dosage form with consistent performance across three ingredients. The main barriers are operational rather than biological.

Manufacturing barriers

Key process risks include:

• Segregation caused by differences in particle size and density.
• Tetracycline degradation under moisture or heat exposure.
• Lubricant overuse and impaired dissolution.
• Capsule-fill weight variability.
• Cross-contamination controls for multiple active ingredients.
• Stability differences among individual actives.
• Color and imprint consistency.
• Packaging validation across global climate zones.

A robust control strategy would define critical material attributes for each active and critical process parameters for blending, lubrication, encapsulation, and packaging.

Regulatory barriers

A generic applicant must address pharmaceutical equivalence for all three actives, capsule performance, impurities, stability, and bioequivalence. The applicant also must manage labeling requirements associated with metronidazole, tetracycline, bismuth, pregnancy warnings, alcohol interaction, photosensitivity, and administration restrictions.

The complexity is greater than for a conventional single-active capsule because failure in one active can compromise the entire product.

Which companies could challenge PYLERA?

Potential challengers include:

• Generic manufacturers with combination-product capabilities.
• Companies with established tetracycline or metronidazole manufacturing platforms.
• Contract development and manufacturing organizations.
• Regional pharmaceutical companies targeting H. pylori therapies.
• Branded gastrointestinal companies pursuing co-pack or lifecycle products.

The most credible challengers are manufacturers that already control high-volume solid-dose production, high-barrier packaging, and regulatory resources for multi-active abbreviated applications. A small company with only conventional capsule capability would face greater process-development risk.

No biosimilar competitor is relevant because PYLERA contains chemically synthesized small-molecule actives, not a biologic.

How does PYLERA compare with competing H. pylori regimens?

PYLERA competes with bismuth quadruple therapy, concomitant therapy, clarithromycin-based regimens, rifabutin-based regimens, and vonoprazan-containing products. Treatment selection depends on local resistance patterns, prior macrolide exposure, guideline recommendations, tolerability, availability, and cost.[3,4]

Product or regimen	Main commercial advantage	Main weakness
PYLERA plus omeprazole	Preassembled bismuth-based combination	12 PYLERA capsules daily plus omeprazole
Individually prescribed bismuth quadruple therapy	Dosing flexibility and potential cost control	Higher prescribing and dispensing complexity
Clarithromycin triple therapy	Familiarity and simpler historical regimen	Resistance limits effectiveness in many settings
Concomitant therapy	Multiple antibacterial mechanisms	More separate products and interaction management
Vonoprazan-based regimens	Potent acid suppression and newer product positioning	Price, access, and regimen-specific resistance considerations
Rifabutin-based therapy	Option after treatment failure	Cost and antimicrobial stewardship concerns

PYLERA’s principal differentiation is regimen consolidation. Its principal competitive weakness is that consolidation still leaves a high daily capsule count.

What revenue exposure and licensing opportunities exist?

AbbVie is the current owner of Allergan’s assets following AbbVie’s acquisition of Allergan in 2020.[5] Public company reporting does not generally disclose PYLERA revenue as a separate line item, so product-specific revenue exposure cannot be calculated reliably from consolidated filings.

The principal commercial opportunities are:

1. Regional licensing to gastrointestinal-focused companies.
2. Authorized-generic supply agreements.
3. Co-packs with omeprazole.
4. Private-label supply for pharmacy and payer channels.
5. Geographic expansion using local blister packaging.
6. Reformulated capsule shells for dietary or regulatory markets.
7. Contract manufacturing of a high-barrier, regimen-specific package.
8. Lifecycle products designed around adherence rather than new antibacterial activity.

A licensing deal would be most attractive where the partner has local registration, reimbursement access, hospital relationships, or manufacturing capacity. The product is less suited to a premium innovation model unless a new formulation demonstrates clinically meaningful improvements in adherence, tolerability, or eradication outcomes.

What is the likely generic launch scenario for PYLERA?

A generic launch could take one of three forms:

Early Paragraph IV entry

A challenger files before all relevant listed patents expire and certifies that the patents are invalid, unenforceable, or not infringed. Litigation may delay approval or launch. The first successful Paragraph IV applicant may obtain 180-day generic exclusivity under applicable Hatch-Waxman rules.

Post-patent conventional entry

A manufacturer waits until relevant patent barriers expire and launches after FDA approval. This is the lower-risk path but may produce lower commercial returns because multiple applicants can enter together.

Authorized-generic or licensed entry

The branded owner or a partner markets an equivalent product under a separate label or commercial arrangement. This can reduce the incentive for an independent challenger and preserve supply-chain control.

The most likely competitive pressure would be price-led entry, followed by formulary substitution and pharmacy-level competition. Product differentiation through blister packaging, capsule-shell composition, or adherence support could slow substitution but would not eliminate ordinary generic pressure.

Key Takeaways

• PYLERA contains bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride in a hard-gelatin capsule.
• The labeled regimen is three capsules four times daily for 10 days with omeprazole twice daily.
• Its main excipients are colloidal silicon dioxide, magnesium stearate, gelatin, titanium dioxide, black iron oxide, and shellac.
• The strongest excipient opportunities concern powder flow, moisture stability, capsule robustness, swallowability, and packaging.
• High-barrier unit-dose blistering is the clearest near-term commercial opportunity.
• Gelatin-free, shellac-free, and titanium-dioxide-free variants could support regional or specialty positioning.
• PYLERA is a small-molecule combination product, so biosimilar competition does not apply.
• Generic development is complicated by three-active content uniformity, dissolution, stability, and packaging requirements.
• PYLERA-specific revenue is not separately disclosed in public AbbVie reporting.
• Orange Book patents, Paragraph IV notices, litigation, settlements, and current expiry dates determine the actual timing of generic entry.

FAQs

Can PYLERA be reformulated as a single tablet?

Technically, a single tablet would be difficult because the three active ingredients require substantial mass, different formulation controls, and independent stability assessment. A high-density tablet or multilayer tablet is possible in principle but would require new pharmaceutical development and likely a comprehensive regulatory strategy.

Does PYLERA contain lactose?

The cited FDA labeling identifies colloidal silicon dioxide and magnesium stearate as inactive ingredients and lists capsule-shell and printing components. Lactose is not identified in that ingredient description.[1]

Is PYLERA suitable for a pediatric formulation?

PYLERA is labeled for adults. A pediatric product would require separate dose, safety, formulation, and regulatory development rather than a simple excipient substitution.[1]

Could a PYLERA blister package support patent protection?

A blister package may support patent or design protection if it includes a novel architecture or produces a demonstrated technical effect, such as improved stability or dose compliance. Routine calendar packaging alone would generally provide narrower protection.

What is the highest-value lifecycle strategy for PYLERA?

The highest-value strategy is a regimen-specific co-pack that improves adherence, integrates omeprazole administration, protects the capsules from moisture, and supports regional distribution. A smaller or more swallowable capsule would offer greater differentiation but would require more extensive formulation and bioequivalence development.

References

1. U.S. Food and Drug Administration. (2024). PYLERA (bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride) capsules: Prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. American College of Gastroenterology. (2024). ACG clinical guideline: Treatment of Helicobacter pylori infection. American Journal of Gastroenterology.
4. Malfertheiner, P., et al. (2022). Management of Helicobacter pylori infection: The Maastricht VI/Florence consensus report. Gut, 71(9), 1724-1762.
5. AbbVie Inc. (2020). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.